LDL Cholesterol Targets for Patients with Diabetes Mellitus and Cardiac Disease
Risk Stratification and Targets
- The European Society of Cardiology recommends that patients with diabetes mellitus and cardiac disease be classified as "very high risk" and have an LDL cholesterol target of <1.4 mmol/L (<55 mg/dL) with at least a 50% reduction from baseline 1, 2, 3
- The primary target for these patients is <1.4 mmol/L (<55 mg/dL), with a minimum reduction of at least 50% from baseline LDL-C, and a secondary target of non-HDL-C <2.2 mmol/L (<85 mg/dL) 1, 2
Treatment Approach
- The European Society of Cardiology recommends statins at maximum tolerated dose as first-line therapy for patients with diabetes and high LDL-C levels 1, 2
- If the target is not reached with statins alone, ezetimibe should be added to statin therapy 1, 2
- If the target is still not reached, a PCSK9 inhibitor (evolocumab, alirocumab) should be added for patients with persistent high LDL-C despite maximum tolerated statin dose plus ezetimibe 1, 2
Evidence Supporting Lower LDL-C Targets
- The 2019 ESC guidelines represent a significant change from previous recommendations, which had set higher targets (previously <2.5 mmol/L or <100 mg/dL for high-risk diabetic patients) 3, 4
Special Considerations
- For patients experiencing a second vascular event within 2 years despite being on maximum tolerated statin therapy, an even lower LDL-C target of <40 mg/dL may be considered 5
Monitoring and Follow-up
- Regular lipid monitoring is essential to ensure targets are maintained, and a standardized follow-up plan should be implemented to maximize adherence to treatment 6
- Consider using direct LDL-C measurement (beta quantification) rather than calculated LDL-C in patients with very low LDL-C levels or elevated triglycerides, as calculated values may be underestimated 5